




NOVEMBER 9–14

VIRTUALLY REIMAGINED

35th Anniversary Annual Meeting and Pre-Conference Programs Schedule



Society for Immunotherapy of Cancer



Pre-Conference Program

Monday, November 9, 2020

Immunotherapy Resistance and Failure

9 a.m.–3:15 p.m. EST

Organizers:

Kald Abdallah, MD, PhD – *Bristol Myers Squibb*

Edward Cha, MD, PhD – *Genentech*

Jennifer Gansert, MD, PhD – *Amgen*

Israel Lowy, MD, PhD – *Regeneron Pharmaceuticals*

Giovanni Melillo, MD – *AstraZeneca*

Eric H. Rubin, MD – *Merck*

Session I: Defining Immune Checkpoint Inhibitor Resistance

- 9–9:05 a.m. **Introduction**
Edward Cha, MD, PhD – *Genentech*
- 9:05–9:35 a.m. **Definitions of Resistance and Gaps in Current Understanding**
Ryan J. Sullivan, MD – *Massachusetts General Hospital*
- 9:35–9:55 a.m. **Mechanisms of Resistance and Possible New Combinations for Overcoming Them**
Paolo A. Ascierto, MD – *Istituto Nazionale Tumori IRCCS Fondazione Pascale*
- 9:55–10:15 a.m. **Immunotherapy Primary and Acquired Resistance**
Antoni Ribas, MD, PhD – *University of California Los Angeles*
- 10:15–10:30 a.m. **Break**

Session II: Primary Resistance

- 10:35–10:55 a.m. **Approaches to Address Primary Resistance**
Siwen Hu-Lieskovan MD, PhD – *Huntsman Cancer Institute, University of Utah*
- 10:55–11:20 a.m. **Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Primary Resistance**
Suzanne L. Topalian, MD – *Johns Hopkins University School of Medicine*
- 11:20–11:35 a.m. **Coupled scRNA-seq and Intracellular Protein Activity Reveals Immune Suppressive Role of TREM2 in Cancer**
Yonatan Katzenelenbogen, B.Sc – *Weizmann Institute of Science*
- 11:35–11:50 a.m. **–MHC-I and -II Expression Levels on Tumor cells and T cell Response to Immunotherapy in B78 Murine Melanoma Model**
Amy K. Erbe, PhD – *University of Wisconsin*
- 11:50–12:20 p.m. **Break**

Session III: Secondary/Acquired Resistance



- 12:20–12:45 p.m. **Approaches to Address Acquired Resistance**
Kevin J. Harrington, PhD, MD - *The Institute of Cancer Research*
- 12:45–1:00 p.m. **Overcoming Acquired Resistance in anti-PD-1 Therapy by Simultaneously Depleting Tumor and All Major Types of Immunosuppressive cells**
Yong Lu, PhD - *Wake Forest School of Medicine*
- 1:00–1:15 p.m. **Preclinical Antitumor Activity of OncoVEXmGM-CSF in Combination with PD-1/PD-L1 Inhibitors in PD-L1 Resistant Mouse Models Supports the MASTERKEY-115 Study**
Jing Qing, PhD - *Amgen Inc.*
- 1:15–1:30 p.m. **Break**

Session IV: Therapeutic Strategies for Patients with Resistant Disease

- 1:30–1:45 p.m. **Assessment of Circulating Tumor DNA (ctDNA) and Plasma Microsatellite Instability (MSI) during PD-1 Blockade**
Pashtoon M. Kasi, MD, MS - *University of Iowa*
- 1:45–2:00 p.m. **Radiological Dynamics and Resistance Types in Patients with Advanced Melanoma Treated with anti-PD-1 Monotherapy**
Xue Bai, MD - *Peking University Cancer Hospital & MGH*
- 2:00–2:15 p.m. **Precision Microbiome Mapping Identifies a Microbiome Signature Predictive of Immune Checkpoint Inhibitor Response Across Multiple Research Study Cohorts**
Matthew J. Robinson, PhD - *Microbiotica*
- 2:15–2:40 p.m. **Regulatory Considerations**
Marc Theoret, MD – *U.S. Food and Drug Administration, OHOP*
- 2:40–3:10 p.m. **Panel Discussion**
Moderators: Jennifer Gansert, MD, PhD – *Amgen*
Israel Lowy, MD, PhD - *Regeneron Pharmaceuticals*
Panelists:
All Speakers
- 3:10–3:15 p.m. **Closing Remarks**
Israel Lowy, MD, PhD - *Regeneron Pharmaceuticals*

Workshop on Engineering Immune Cells for Cancer Therapy

9 a.m.–2:55 p.m. EST

Organizers:

Christine Brown, PhD – *City of Hope*
Katayoun Rezvani, MD, PhD – *The University of Texas MD Anderson Cancer Center*
Marco Ruella, MD – *University of Pennsylvania*

Session I: Advances in Adoptive T cell Therapy for Cancer: TILs and TCRs

- 9–9:05 a.m. **Introduction**
Katayoun Rezvani, MD, PhD - *The University of Texas MD Anderson Cancer Center*
- 9:05–9:25 a.m. **Cellular Immunotherapy for Metastatic Cancers**
Steven A. Rosenberg, MD, PhD - *National Cancer Institute, National Institutes of Health*



- 9:25–9:45 a.m. **Adoptive Therapy Utilizing TILs**
John Haanen, MD, PhD - *Netherlands Cancer Institute*
- 9:45–10:05 a.m. **Endogenous T cell Therapy for Solid Tumors Malignancies**
Cassian Yee, MD - *The University of Texas MD Anderson Cancer Center*
- 10:05–10:20 a.m. **Session I Panel Discussion - Session I Speakers**
- 10:20–10:35 a.m. **Break**

Session II: Novel Approaches to Enhance CAR T cell Therapy


- 10:35–10:55 a.m. **Next-generation CARS for blood cancers**
Michael Hudecek, MD - *University of Wuerzburg*
- 10:55–11:15 a.m. **Advancing Immunotherapy Platforms for the Treatment of Solid Tumors**
Saul Priceman, PhD - *City of Hope*
- 11:15–11:35 a.m. **Understanding Resistance to CAR T-cell Therapy to Develop Next-generation Immunotherapies**
Marco Ruella, MD - *University of Pennsylvania*
- 11:35–11:50 a.m. **Session II Panel Discussion - Session II Speakers**
- 11:50 a.m.–12:05 p.m. **Break**

Session III: CAR-Based Strategies Beyond T Lymphocytes

- 12:05–12:25 p.m. **CAR NK cells for the Immunotherapy of Cancer**
Katy Rezvani, MD, PhD - *The University of Texas MD Anderson Cancer Center*
- 12:25–12:45 p.m. **The Development of CAR Macrophages and Monocytes for Cancer Immunotherapy**
Michael Klichinsky, PharmD, PhD - *Carisma Therapeutics*
- 12:45–1:05 p.m. **Engineering B cells to Produce Therapeutic Antibodies**
Justin Taylor, PhD - *Fred Hutchinson Cancer Research Center*
- 1:05–1:20 p.m. **Session III Panel Discussion - Session III Speakers**
- 1:20–1:35 p.m. **Break**

Session IV: Integration of Novel Technologies for CAR Therapy and their Translation to the Clinic

- 1:35–1:55 p.m. **The Evolving Process of Clinical CAR T Cell Manufacturing in the Academic Setting**
Isabelle Riviere, PhD - *Memorial Sloan Kettering Cancer Center*
- 1:55–2:15 p.m. **Allogeneic CAR T therapy for Cancer**
Barbra J. Sasu, PhD - *Allogene Therapeutics*
- 2:15–2:35 p.m. **Corona Madness: Flattening the Curve with CAR T**
Carl H. June, MD - *University of Pennsylvania*
- 2:35–2:50 p.m. **Session IV Panel Discussion - Session IV Speakers**



2:50–2:55 p.m. **Closing Remarks**
Christine Brown, PhD – *City of Hope*

Pre-Conference Program

Tuesday, November 10, 2020

7:30–8:30 a.m. EST **Sponsored Symposia: Medscape: A Deep Dive Into Immunotherapy in Advanced Endometrial Cancer**

World Immunotherapy Council's Virtual Young Investigator Session

8–9 a.m. EST

Organizers:

Bernard A. Fox, PhD - *Providence Cancer Institute*

Tanja D. de Gruijl, PhD - *VU University Amsterdam*

8–8:05 a.m. **Introduction**
Bernard A. Fox, PhD - *Providence Cancer Institute*

8:05–8:15 a.m. **A combination of functional biomarkers improves identification of the tumor-specific reactive T cell repertoire**
Arianna Draghi - *Karolinska University Hospital*

8:15–8:25 a.m. **Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients**
Denise Goh, BBiomedSc (Hons) - *Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore*

8:25–8:30 a.m. **Expert Discussant**
Tanja D. de Gruijl, PhD - *VU University Amsterdam*

8:30–8:40 a.m. **Anti-LunX targeting therapy for lung cancer**
Xiaohu Zheng - *University of Science and Technology of China*

8:40–8:50 a.m. **Identification of tumor antigen-specific T cells in the peripheral blood of colorectal cancer patients**
Emilie Picard, PhD - *Health Sciences North/Horizon Sante Nord*

8:50–8:55 a.m. **Expert Discussant**
Bernard A. Fox, PhD - *Providence Cancer Institute*

8:55–9 a.m. **Closing Remarks**
Bernard A. Fox, PhD - *Providence Cancer Institute*


Grant Writing Workshop

9–11:45 a.m. EST

Organizers:

Grey Wilkinson, PhD – *Oncolytics Biotech Inc.*

Olivia Rongze Lu, PhD – *University of Texas at Austin, Dell Medical School*



Chair Claire Vanpouille-Box, PhD – *Weill Cornell Medicine*
David Aggen, MD, PhD – *Memorial Sloan Kettering Cancer Center*

9–9:05 a.m. **Welcome Remarks**

Claire Vanpouille-Box, PhD – *Weill Medical College of Cornell University*

9:05–9:30 a.m. **Overview of Grant Opportunities and Principles of Grant Writing**

Pawel Kalinski, MD, PhD – *Roswell Park Comprehensive Cancer Institute*

9:30–9:55 a.m. **K Awards and R01 Grants**

William Matsui, MD – *University of Texas at Austin*

9:55–10:30 a.m. **How to Write a Specific Aims Page**

Thomas Gajewski, MD, PhD – *University of Chicago*

10:30–10:45 a.m. **Panel Discussion**

Moderator:

David Aggen, MD, PhD – *Memorial Sloan Kettering Cancer Center*

Panelists:

William Matsui, MD – *University of Texas at Austin*

Thomas Gajewski, MD, PhD – *University of Chicago*

Pawel Kalinski, MD, PhD – *Roswell Park Comprehensive Cancer Institute*

Malgorzata Klauzinska, PhD – *National Institutes of Health*

10:45–11:10 a.m. **Mock Study Section**

Moderator:

Zhang-Zhi Hu, MD- *National Institute of Health*

Panelists:

Scientific Review Officer - Malgorzata Klauzinska, PhD – *National Institutes of Health*

Chair - Thomas Gajewski, PhD – *University of Chicago*

Primary Reviewer - Pawel Kalinski, MD, PhD – *Roswell Park Comprehensive Cancer Institute*

Secondary Reviewer - William Matsui, MD – *University of Texas at Austin*

Third Reviewer – Robyn Gartrell, MD – *Columbia University/New York Presbyterian*

Reader - Olivia Rongze Lu, PhD – *University of Texas at Austin, Dell Medical School*

11:10–11:30 a.m. **What Happens After the Study Section?**

Malgorzata Klauzinska, PhD – *National Institutes of Health*

11:30–11:40 a.m. **Panel Discussion**

Moderator:

Grey Wilkinson, PhD – *Oncolytics Biotech Inc.*

Panelists:

William Matsui, MD – *University of Texas at Austin*

Thomas Gajewski, PhD – *University of Chicago*

Pawel Kalinski, PhD – *Roswell Park Comprehensive Cancer Institute*

Malgorzata Klauzinska, PhD – *National Institutes of Health*

Zhang-Zhi Hu, MD- *National Institute of Health*

11:40–11:45 a.m. **Closing Remarks**

Olivia Rongze Lu, PhD – *University of Texas at Austin, Dell Medical School*

Primer on Tumor Immunology and Cancer Immunotherapy™

9 a.m.–4 p.m. EST

Organizers:

Michael A. Curran, PhD – *The University of Texas MD Anderson Cancer Center*



Yvonne Saenger, MD – *Columbia University Irving Medical Center*

Session I: Generating Anti-Tumor Immunity


- 9–9:05 a.m. **Introduction**
Michael A. Curran, PhD – *The University of Texas MD Anderson Cancer Center*
- 9:05–9:35 a.m. **The Adaptive Immune Response**
Jonathan D. Powell, MD, PhD – *Johns Hopkins University School of Medicine*
- 9:35–10 a.m. **Antigen Presenting Cells**
Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai*
- 10–10:25 a.m. **Myeloid-derived Suppressor Cells as Negative Regulators of Immune Responses in Cancer**
Dmitry I. Gabrilovich, MD, PhD – *AstraZeneca*
- 10:25–10:40 a.m. **Session I Panel Discussion - Session I Speakers**
- 10:40–10:55 a.m. **Break**

Session II: Approaches to Immunotherapy I

- 10:55–11 a.m. **Introduction**
Michael A. Curran, PhD – *The University of Texas MD Anderson Cancer Center*
- 11–11:25 a.m. **T cell Checkpoint Blockade/Costimulation**
James P. Allison, PhD – *University of Texas MD Anderson Cancer Center*
- 11:25–11:50 a.m. **Cancer Vaccines**
Ugur Sahin, MD – *BioNTech Group*
- 11:50 a.m.–12:15 p.m. **The Suppressive Yin Versus Pro-Inflammatory Yang of the Tumor Myeloid Stroma**
Michael A. Curran, PhD – *The University of Texas MD Anderson Cancer Center*
- 12:15–12:30 p.m. **Session II Panel Discussion - Session II Speakers**
- 12:30–12:50 p.m. **Break**

Session III: Approaches to Immunotherapy II

- 12:50–12:55 p.m. **Introduction**
Yvonne Saenger, MD – *Columbia University Irving Medical Center*
- 12:55–1:20 p.m. **Be all that you can B: Imprinting an Antitumor T cell Army**
Chrystal M. Paulos, PhD – *Emory University*
- 1:20–1:45 p.m. **Immunometabolism and its Potential to Modify the Tumor Microenvironment**
Greg M. Delgoffe, PhD – *University of Pittsburgh*
- 1:45–2:10 p.m. **Mobilizing the Immune System with Bispecific Antibodies**
John R. Desjarlais, PhD – *Xencor, Inc*



2:10–2:25 p.m. **Session III Panel Discussion - Session III Speakers**

2:25–2:40 p.m. **Break**

Session IV: Clinical Practice of Immunotherapy

2:40–2:45p.m. **Introduction**
Yvonne Saenger, MD – *Columbia University Irving Medical Center*

2:45–3:10 p.m. **Immune Biomarkers to Guide Clinical Care**
Yvonne Saenger, MD – *Columbia University Irving Medical Center*

3:10–3:35 p.m. **Immune Related Adverse Events**
Michael A. Postow, MD – *Memorial Sloan Kettering Cancer Center*

3:35–3:50 p.m. **Session IV Panel Discussion - Session IV Speakers**

3:50–4 p.m. **Closing Remarks**
Yvonne Saenger, MD – *Columbia University Irving Medical Center*

35th Anniversary Annual Meeting

Wednesday, Nov. 11, 2020

8–8:30 a.m. EST **Sponsored Symposia: Natera: Deep Dive into the Clinical Utility of Personalized MRD Monitoring**

Anniversary Award Ceremony

8:30–9 a.m. EST

Chair:

Mario Sznol, MD – *Yale School of Medicine*

8:30–9 a.m. **Introduction**
Mario Sznol, MD – *Yale School of Medicine*
Public Service Award
Patient Advocacy Award

Session 100: Presidential Welcome & Rosenberg Award Announcement

9–9:30 a.m. EST

Chair:

Mario Sznol, MD – *Yale School of Medicine*

9–9:30 a.m. **Presidential Welcome**
Mario Sznol, MD – *Yale School of Medicine*

Session 101: Richard V. Smalley, MD Memorial Award and Lectureship: Discovery, Development, and Application of the PD-1/PD-L1; B7-H1 Antagonist Antibodies

9:30–11 a.m. EST

Chair:



Mario Sznol, MD – *Yale School of Medicine*

9:30–10 a.m. **The PD-L1/PD-1 Pathway: Discovery and New Insights**
Gordon Freeman, PhD – *Dana-Farber Cancer Institute*

10–10:30 a.m. **Why were we interested in immunity within the tumor microenvironment in the 1990s?**
Lieiping Chen, MD, PhD – *Yale School of Medicine*

10:30–11 a.m. **Discovery of New IO Targets and Mechanisms Leveraging CRISPR**
Arlene Sharpe, MD, PhD – *Harvard Medical School*

Break

11–11:15 a.m.

Session 102: Combinatorial Therapies

11:15 a.m.–1:10 p.m. EST

Co-Chairs:

Charlotte E. Ariyan, MD, PhD – *Memorial Sloan Kettering Cancer Center*

Silvia Formenti, MD – *Weill Cornell Medicine*

11:15–11:20 a.m. **Introduction**

11:20–11:30 a.m. **(470) Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors**
Nicholas Zorko, MD, PhD – *University of Minnesota*

11:30–11:40 a.m. **(446) Immunoepitope changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition**
Peter Joyce, PhD – *Grey Wolf Therapeutics Limited*

11:40–11:50 a.m. **(362) A Phase I study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis**
James Spicer, PhD, FRCP – *King's College London*

11:50 a.m.–12:05 p.m. **Expert Discussant**
Charlotte E. Ariyan, MD, PhD – *Memorial Sloan Kettering Cancer Center*


12:05–12:15 p.m. **Q&A**

12:15–12:25 p.m. **(200) NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant Murine Lung Cancer Model**
Yun Hu, PhD – *The University of Texas MD Anderson Cancer Center*

12:25–12:35 p.m. **(368) REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors**
Adi Diab, MD – *The University of Texas MD Anderson Cancer Center*

12:35–12:45 p.m. **(386) Phase I/II first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15R α heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors**
John Thompson, MD – *University of Washington Seattle Cancer Care*

12:45–1 p.m. **Expert Discussant**
Chandan Guha, MB, BS, PhD – *Montefiore Medical Center*



1–1:10 p.m. **Q&A**

Break

1:10–1:30 p.m.

Virtual Exhibit Hall & Poster Hall Hours

1–2 p.m.

Concurrent Rapid Oral Abstract Presentation Session 103: Basic Research

1:30–2 p.m. EST

Co-Chairs:

Sarah Church, PhD – *NanoString Technologies*

Brendan Horton, PhD – *Massachusetts Institute of Technology*

1:30–1:38 p.m. **(90) Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway**
Jonathan Boiarsky, BA - *Icahn School of Medicine at Mount Sinai*

1:38–1:46 p.m. **(209) Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasone's detrimental effects on immune checkpoint blockade in glioblastoma cancer**
Bryan Iorgulescu, MD - *Dana-Farber Cancer Institute*

1:46–1:54 p.m. **(472) ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma**
Natasha D. Sheybani, PhD - *University of Virginia*

1:54–2 p.m. **Q&A**

Concurrent Rapid Oral Abstract Presentation Session 104: Clinical

1:30–2 p.m. EST

Co-Chairs:

Ravi Patel, MD, PhD – *University of Pittsburgh*

Jessica Thaxton, PhD, MSCR – *Medical University of South Carolina*

1:30–1:38 p.m. **(420) Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study**
Adi Diab, MD - *The University of Texas MD Anderson Cancer Center*

1:38–1:46 p.m. **(547) Identification of the immune landscape in penile squamous cell carcinoma using multiplex immunofluorescence and spatial image analysis**
Rosanna N. Lazcano Segura, MD - *The University of Texas MD Anderson Cancer Center*

1:46–1:54 p.m. **(455) Impact of EphB4 and PD-1 treatment on immune infiltrate in advanced bladder cancer**
Sarmad Sadeghi, MD - *Keck School of Medicine of USC*

1:54–2 p.m. **Q&A**

Session 105: Integrating Radiation and Immunotherapy: New Products, Challenges, and Opportunities for Industry-Academic Collaborations

2–3:30 p.m. EST

Co-Chairs:

Zachary Morris, MD, PhD – *University of Wisconsin, Madison*

Andrew Sikora, MD, PhD – *The University of Texas MD Anderson Cancer Center*

2–2:05 p.m. **Introduction**
Andrew Sikora, MD, PhD – *The University of Texas MD Anderson Cancer Center*

2:05–2:20 p.m. **The Immuno-Radiobiology of Radiation Therapy**



Zachary Morris, MD, PhD – *University of Wisconsin, Madison*

2:20–2:35 p.m.

Optimal Sequencing of Radiation and Immunotherapy

Silvia Formenti, MD – *Weill Cornell Medicine*

2:35–2:50 p.m.

Design of Clinical Trials Integrating Radiation and Immunotherapy

Jonathan D. Schoenfeld, MD, MPhil, MPH – *Harvard University*

2:50–3 p.m.

NCI SBIR Opportunities

Kory Hallet, PhD – *NCI SBIR Development Center*

3–3:25 p.m.

Best Practices and Future Perspectives for Integrating Radiation and Immunotherapy Panel Discussion

Mansoor Ahmed, PhD – *National Cancer Institute*

Michael Bassetti, MD, PhD – *University of Wisconsin-Madison*

Sue L. Currie, PhD – *Nektar Therapeutics*

Sandra Demaria, MD – *Weill Cornell Medicine*

Silvia Formenti, MD – *Weill Cornell Medicine*

Kory Hallet, PhD – *NCI SBIR Development Center*

Tibor Keler, PhD – *Celldex Therapeutics, Inc.*

Sophia Pfister, PhD – *Varian*

Jonathan D. Schoenfeld, MD, MPhil, MPH – *Harvard University*

Andrew Sharabi, MD, PhD – *Moore's Cancer Center*

Kristina H. Young, MD, PhD – *Earle A. Chiles Research Institute*

Samir Khleif, MD – *Georgetown University Medical Center*

Chiayeng Wang, PhD – *National Cancer Institute, NIH*

Paul Sondel, MD, PhD – *University of Wisconsin-Madison*

3:25–3:30 p.m.

Closing Remarks

Break

3:30–3:45 p.m.

Concurrent Session 106: Developing Cellular Therapies for Solid Cancers

3:45–5:15 p.m. EST

Co-Chairs:

Stephanie L. Goff, MD, FACS – *National Cancer Institute*

Avery Posey, PhD – *University of Pennsylvania School of Medicine*

3:45–4:05 p.m.

TILs

Michal Besser, PhD – *The Sheba Medical Center at Tel Hashomer*

4:05–4:25 p.m.

TCR Cells

James C. Yang, MD – *National Cancer Institute*

4:25–4:45 p.m.

CAR for Solid Tumors

Avery Posey, PhD – *University of Pennsylvania School of Medicine*

4:45–5:05 p.m.

NKT Cells

Andras A. Heczey, MD – *Baylor College of Medicine*

5:05–5:15 p.m.

(122) Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model

Amanda N. Lisby, MS – *Thomas Jefferson University*

Concurrent Session 107: Neoadjuvant Immunotherapies

3:45–5:15 EST

**Co-Chairs:**

Padmanee Sharma, MD, PhD – *The University of Texas MD Anderson Cancer Center*

Janis M. Taube, MD, MSc – *Johns Hopkins School of Medicine*

3:45–4:05 p.m.

Pan-Tumor Pathologic Response Assessment

Janis M. Taube, MD, MSc – *Johns Hopkins University School of Medicine*

4:05–4:25 p.m.

Neoadjuvant Breast Cancer

Elizabeth A. Mittendorf, MD, PhD – *Dana-Farber Cancer Institute*

4:25–4:45 p.m.

Bladder Cancer (Treme/Durva)

Jianjun Gao, MD, PhD – *The University of Texas MD Anderson Cancer Center*

4:45–5 p.m.

(432) 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma

Reinhard Dummer, MD – *University Hospital of Zurich*

5–5:15 p.m.

(264) Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma

Raquel Deering, PhD – *Regeneron Pharmaceuticals, Inc.*

Concurrent Session 108: Diet and Microbiome

3:45–5:15 p.m. EST

Co-Chairs:

Jeremiah Faith, PhD – *Icahn Institute for Data Science and Genomic Technology at Mt. Sinai*

Laurence Zitvogel, MD, PhD – *Institut Gustave Roussy*

3:45–4 p.m.

Introduction into Microbiome & Diet

Jeremiah Faith, PhD – *Icahn Institute for Data Science and Genomic Technology at Mt. Sinai*

4–4:20 p.m.

Micronutrients with Immunostimulatory Properties

Guido Kroemer, MD, PhD – *Institut Gustave Roussy*

4:20–4:40 p.m.

Linking the gut microbiome to cancer immunotherapy response

Meriem Messaoudene, PhD – *CRCHUM, Bertrand Routy Lab*

4:45–5:05 p.m.

Diet, the microbiome, and immune response: From observation to intervention

Jennifer L. McQuade, MD – *The University of Texas MD Anderson Cancer Center*

5:05–5:15 p.m.

(672) Identification of microbial-derived HLA-bound peptides in melanoma

Adi Nagler, MSc – *Weizmann*

Concurrent Session 109: Innate Immunity: The Next Generation of targets for Anti-Cancer Immunotherapy

3:45–5:15 p.m. EST

Co-Chairs:

Jennifer L. Guerriero, PhD – *Dana-Farber Cancer Institute*

Katayoun Rezvani, MD, PhD – *The University of Texas MD Anderson Cancer Center*

3:45–4:05 p.m.

Harnessing Tumor Associated Macrophages for Anti-Cancer Therapy

Jennifer L. Guerriero, PhD – *Dana-Farber Cancer Institute*

4:05–4:25 p.m.

Gamma-delta T cells

Adrian Hayday, FRS, F MedSci – *Gamma Delta Therapeutics*

4:25–4:45 p.m.

NK cells

Andreas Lundqvist, PhD – *Karolinska Institutet*



4:45–5 p.m. **(531) AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies**

Nancy D. Marin, PhD - *Washington University, St. Louis*

5–5:15 p.m. **(539) High dimensional analysis of the human lymph node during melanoma progression reveals shifts in myeloid content that relate to differential T cell content**

Anastasia Prokopi, PhD - *Amsterdam, UMC*

Virtual Exhibit Hall & Poster Hall Hours

5–6 p.m.

Session 110: E-Poster Viewing Session

5:15–5:45 p.m. EST

Session 111: The Surgeon's Impact on Tumor Immunotherapy: Recent Achievements and Future Promise

5:30–6:30 p.m. EST

Co-Chairs:

Howard L. Kaufman, MD, FACS – *Immuneering Corporation*

Brian R. Gastman, MD – *Cleveland Clinic Cancer Center*

5:30–5:35 p.m. **Introduction**

Brian R. Gastman, MD – *Cleveland Clinic Cancer Center*

5:35–5:45 p.m. **Oncolytic Viruses: The Importance of Surgical Input**

Howard L. Kaufman, MD, FACS – *Immuneering Corporation*

5:45–5:50 p.m. **(274) Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced Non-Small Cell Lung Cancer**

Maria L. Ascierto, PhD – *AstraZeneca*

5:50–5:55 p.m. **(277) Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy**

Boris Sepesi, MD - *The University of Texas MD Anderson Cancer Center*

5:55–6:00 p.m. **(303) Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High-Risk Resectable Melanoma (Neo-C-Nivo): Final Results**

Diwakar Davar, MD – *UPMC Hillman Cancer Center*

6–6:05 p.m. **(449) Neoadjuvant cyclic dinucleotides combined with interleukin-2 and anti-PD-1 antibody limit lung metastasis of orthotopic breast tumors through prolonged NK cell activation**

Lauren Milling, BS – *Massachusetts Institute of Technology*

6:05–6:10 p.m. **(254) CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors**

Roberta Zappasodi, PhD - *Memorial Sloan Kettering Cancer Center*

6:10–6:20 p.m. **Expert Discussant**


Steven A. Rosenberg, MD, PhD – *National Cancer Institute, National Institutes of Health*

6:20–6:30 p.m. **Q&A**

Break

6:30–7 p.m.

Replay Session with Live Q&A: Rapid Oral Abstracts: Basic Research



7–8 p.m. EST

Co-Chairs:

Sarah Church, PhD – *NanoString Technologies*

Brendan Horton, PhD – *Massachusetts Institute of Technology*

Replay Session with Live Q&A: Rapid Oral Abstracts - Clinical

7–8 p.m. EST

Co-Chairs:

Ravi Patel, MD, PhD – *University of Pittsburgh*

Jessica Thaxton, PhD, MSCR – *Medical University of South Carolina*

35th Anniversary Annual Meeting

Thursday, Nov. 12, 2020

7:30–8:30 a.m.
EST

**Sponsored Symposia: OncoSec-DNA Plasmid-based IL-12 Delivered Intratumoral Electroporation:
Achieving Meaningful Tumor Responses While Avoiding Systemic Toxicities**

Anniversary Award Ceremony

8:30–9 a.m. EST

Chair:

Mario Sznol, MD – *Yale School of Medicine*

8:30–8:32 a.m.

Introduction

Mario Sznol, MD – *Yale School of Medicine*

8:32–8:41 a.m.

Extraordinary Service Awards

8:42–8:44 a.m.

Introduction

Mario Sznol, MD – *Yale School of Medicine*

8:44–8:54 a.m.

Visionary/Legacy Award

Session 201: Keynote Address

9–9:50 a.m. EST

Chair:

Mario Sznol, MD – *Yale School of Medicine*

9–9:05 a.m.

Introduction

Mario Sznol, MD – *Yale School of Medicine*

9:05–9:45 a.m.

Turning Immunologically Quiescent Tumors into Immune Responsive Cancers

Elizabeth M. Jaffee, MD – *Sidney Kimmel Cancer Center, Johns Hopkins University*

9:45–9:50 a.m.

Q&A

Elizabeth M. Jaffee, MD – *Sidney Kimmel Cancer Center, Johns Hopkins University*

Break

9:50–10:05 a.m.

Session 201: Exploring the Tumor Microenvironment

10:05–noon EST



Co-Chairs:

Vincenzo Bronte, MD – *University of Verona*

Miriam Merad, MD, PhD – *Icahn School of Medicine at Mount Sinai*

10:05–10:15 a.m. **Introduction**

10:15–10:40 a.m. **Stromal Cells in Health, Disease and Immunotherapy**

Shannon J. Turley, PhD – *Genentech Inc.*

10:40–11:05 **Exploring and Exploiting the Immune Landscape in Brain Cancers**

Johanna A. Joyce, PhD – *University of Lausanne & Ludwig Institute for Cancer Research*

11:05–11:30 a.m. **Investigating Genetic Control of the Tumor Microenvironment by Spatial Functional Genomics**

Brian D. Brown, PhD – *Icahn School of Medicine at Mount Sinai*

11:30–11:45 a.m. **(670) TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy**

Jane Meng, PhD – *I-Mab Biopharma*

11:45 a.m.–noon **(591) Comparison of Two oHSV Vectors for the Treatment of Glioblastoma**

Joseph Jackson, PhD – *University of Pittsburgh*

Session 202: Late-Breaking Abstract Session

Noon–12:30 p.m. EST

Chair:

Sandra Demaria, MD – *Weill Cornell Medicine*

Noon–12:15 p.m. **(773) Phenotypic Correlates of Adoptive Cell Therapy Response in Melanoma**

Sri Krishna, PhD – *National Cancer Institute*

12:15–12:30 p.m. **(788) Pembrolizumab for Patients with Leptomeningeal Metastasis from Solid Tumors: Efficacy, Safety and Cerebrospinal Fluid Biomarkers**

Jarushka Naidoo, MBBCH, MHS – *Johns Hopkins Sidney Kimmel Cancer Center*

Break

12:30–2 p.m.

Concurrent Session 203: Rapid Oral Abstract Presentation: Basic Research

12:50–1:20 p.m. EST

Co-Chairs:

Kristin Anderson, PhD – *Fred Hutchinson Cancer Research Center*

Spencer Wei, PhD – *Spotlight Therapeutics*

12:50–12:58 p.m. **(512) Terminally exhausted CD8⁺ T cells potentiate the tolerogenic tumor microenvironment as functional suppressors**

Paolo D.A. Vignali, BS – *The University of Pittsburgh School of Medicine*

12:58–1:06 p.m. **(755) CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity**

Alvaro Teijeira – *CIMA Pamplona*

1:06–1:14 p.m. **(517) Regulatory T cell functional identity is sustained by a glucose:lactate axis that is exploited in the tumor microenvironment**

McLane Watson, BS – *University Of Pittsburgh*

1:14–1:20 p.m. **Q&A**

Concurrent Session 204: Rapid Oral Abstract Presentation: Clinical



12:50-1:20 p.m. EST

Co-Chairs:

Robyn Gartrell, MD, MS – *Columbia University*

Saman Maleki, PhD – *Western University*

12:50-12:58 p.m. **(294) CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: a phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody**

Michael D. Farwell, MD - *University of Pennsylvania*

12:58-1:06 p.m. **(588) Targeting GITR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases**

Yannick S. Rakké, MD, MSc - *Erasmus University Medical Center*

1:06-1:14 p.m. **(31) Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients**

Diego de Miguel Perez, PhD, MSc - *University of Maryland*

1:14-1:20 p.m. **Q&A**

Session 205: Toxicities of Cancer Immunotherapies

1:20-3:05 p.m. EST

Co-Chairs:

Caroline Robert, MD, PhD – *Institut Gustave Roussy*

Cameron J. Turtle, MBBS, PhD, FRACP – *Fred Hutchinson Cancer Research Center*

1:20-1:45 p.m. **Toxicities from ICIs**

Caroline Robert, MD, PhD – *Institut Gustave Roussy*

1:45-2:10 p.m. **Factors Associated with Toxicities of CD19 CAR-T cell Immunotherapy**

Cameron J. Turtle, MBBS, PhD, FRACP – *Fred Hutchinson Cancer Research Center*

2:10-2:35 p.m. **CAR-T Studies**

Ansuman T. Satpathy, MD, PhD – *Stanford*

2:35-2:50 p.m. **(653) Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release**

Gabrielle Leclercq, MSc - *Roche*

2:50-3:05 p.m. **(645) Preclinical development of a novel colon-targeted therapeutic for the treatment of Immune Checkpoint Inhibitor (ICI)-colitis**

Nazli Dizman, MD - *Yale New Haven Hospital*

Break

3:05-3:20 p.m.

Concurrent Session 206: Vaccines and Immunoprevention

3:20-4:50 p.m. EST

Co-Chairs:

Shizuko Sei, MD – *National Cancer Institute*

Catherine J. Wu, MD – *Dana-Farber Cancer Institute*

3:20-3:50 p.m. **Personal Cancer Vaccines: on the Path to Effective Cancer Immunity**

Catherine J. Wu, MD – *Dana-Farber Cancer Institute*

3:50-4:20 p.m. **Cancer Vaccines for Lynch Syndrome Carrier**

Eduardo Vilar-Sanchez, MD, PhD – *The University of Texas MD Anderson Cancer Center*



- 4:20–4:35 p.m. **(598) Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes**
Rana Falahat, PhD – *Moffit Cancer Center*
- 4:35–4:50 p.m. **(612) Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells**
Kristen Radford, PhD – *Mater Research Institute*

Concurrent Session 207: Gene Editing

3:20–4:50 p.m. EST

Co-Chairs:

Helen E. Heslop, MD – *Baylor College of Medicine*

Carl H. June, MD – *University of Pennsylvania*

3:20–4:50 p.m. **Panelists**

Matthew Porteus, MD, PhD – *Stanford University*

Vijay Peddareddigari, MD – *Tmunity*

Zhaohui Ye, PhD, PI Regulatory – *FDA, Center for Biologics Evaluation and Research*

Chrystal Louis, MD, MPH – *CRISPR Therapeutics*

Concurrent Session 208: Bispecific Antibodies in Cancer Immunotherapy

3:20–4:50 p.m. EST

Co-Chairs:

Dimitris Skokos, PhD – *Regeneron Pharmaceuticals, Inc.*

Mario Sznol, MD – *Yale School of Medicine*

3:20–3:40 p.m. **Human Costimulatory Bispecifics Antibodies in Cancer Immunotherapy**

Dimitris Skokos, PhD – *Regeneron Pharmaceuticals, Inc.*

3:40–4 p.m. **PD1-IL2v: A Next Generation, PD-1-targeted IL-2R Agonist for Cancer Immunotherapy**

Pablo Umana, PhD – *Roche Glycart AG*

4–4:15 p.m. **(633) Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor**

Michelle H. Nelson, PhD – *Aptevo Therapeutics*

4:15–4:30 p.m. **(632) HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors**

Jack Lin, PhD – *Harpoon Therapeutics*

4:30–4:45 p.m. **(359) AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results**

Hossein Borghaei, MS, DO – *Fox Chase Cancer Center*

Concurrent Session 209: Immunometabolism and ICI Resistance

3:20–4:50 p.m. EST

Co-Chairs:

Susan M. Kaech, PhD – *Salk Institute*


Maxim N. Artyomov, PhD – *Washington University School of Medicine in St. Louis*

3:20–3:45 p.m. **Metabolic Regulation of Anti-Tumor NK cells**

Susan M. Kaech, PhD – *Salk Institute*

3:45–4:10 p.m. **Metabolic Processes that Affect Anti-Tumor Immune Responses**

Santosh Vardhana, MD, PhD – *Memorial Sloan Kettering Cancer Center*



4:10–4:35 p.m. **Targeting Metabolism to Enhance Cancer Immunotherapy**
Jonathan D. Powell, MD, PhD – *Johns Hopkins Medicine*

4:35–4:50 p.m. **(515) Metabolic reprogramming of antitumor CD8+ T cell immunity**
Alison Jaccard, MS – *Université de Lausanne*

Session 210: E-Poster Viewing Session

4:50–5:20 p.m. EST

Virtual Exhibit and Poster Hall Hours

5–6 p.m. EST

Replay Session with Live Q&A: Rapid Oral Abstracts: Basic Research

7–8 p.m. EST

Co-Chairs:

Kristin Anderson, PhD – *Fred Hutchinson Cancer Research Center*

Spencer Wei, PhD – *Spotlight Therapeutics*

Replay Session with Live Q&A: Rapid Oral Abstracts: Clinical

7–8 p.m. EST

Co-Chairs:

Robyn Gartrell, MD, MS – *Columbia University*

Saman Maleki, PhD – *Western University*

Replay Session with Live Q&A: Rapid Oral Abstracts: Rapid Oral Abstracts

7–8 p.m. EST

Chair:

Sandra Demaria, MD – *Weill Cornell Medicine*

35th Anniversary Annual Meeting

Friday, Nov. 13, 2020

SITC Membership Business Meeting

8–8:30 a.m. EST

Chair:

Mario Sznol, MD – *Yale School of Medicine*

Anniversary Award Ceremony

8:30–9 a.m. EST

Chair:

Mario Sznol, MD – *Yale School of Medicine*

8:30–8:32 a.m. **Introduction**
Mario Sznol, MD – *Yale School of Medicine*

8:32–8:37 a.m. **Extraordinary Service to JITC Awards**

8:37–8:47 a.m. **Collaboration Awards**

8:47–8:51 a.m. **NCI Collaboration**

8:51–9 a.m. **Closing**



Mario Sznol, MD – *Yale School of Medicine*

Session 300: 35th Anniversary Keynote: T cell Therapy of Cancer

9–9:50 a.m. EST

Chair:

Mario Sznol, MD – *Yale School of Medicine*

9–9:05 a.m.

Introduction

Mario Sznol, MD – *Yale School of Medicine*

9:05–9:45 a.m.

T cell Therapy of Cancer

Helen E. Heslop, MD – *Baylor College of Medicine*

9:45–9:50 a.m.

Q&A

Break

9:50–10:05 a.m.

Session 301: Hot Topic Symposium: COVID-19 and Cancer

10:05–12:40 p.m. EST

Co-Chair:

Jedd D. Wolchok, MD, PhD – *Memorial Sloan Kettering Cancer Center*

Nina Bhardwaj, MD, PhD – *The Tisch Institute, Icahn School of Medicine at Mt Sinai*

10:05–10:30
a.m.

Infection/Immunology

Florian Krammer, PhD – *Icahn School of Medicine at Mount Sinai*

10:30–10:55
a.m.

Infection in Cancer Patients Specifically

Elizabeth V. Robilotti, MD, MPH – *Memorial Sloan Kettering Cancer Center*

10:55–11:05
a.m.

Break

11:05–11:15
a.m.

Repurposing Cancer Immunotherapies for COVID

Paolo Ascierto, MD – *Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale*

11:15–11:25
a.m.

Big Data and Informatics – Viral Sequencing and Epitope Identification

Benjamin Greenbaum, MD – *Memorial Sloan Kettering Cancer Center*

11:25–11:35
a.m.

Big data and Informatics – Viral Sequencing and Epitope Identification

Marta Luksa, PhD – *Icahn School of Medicine at Mount Sinai*

11:35–11:55
a.m.

Q&A

11:55–12:15
p.m.

Panel Discussion: Immunotherapy and COVID Outcomes (ICIs) and Cancer Care in Pandemic


Jia Luo, MD – *Memorial Sloan Kettering Cancer Center*

Aljosja Rogiers, MD – *Institute of Melanoma*

12:15–12:25
p.m.

(325) Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memorial B cells and memory T effector cells

Gerard Criner, MD – *Temple University*



12:25–12:35 p.m. **(475) Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment**
Chun Chau Lawrence Cheung, BA, MMedSc - *Singapore General Hospital*

12:35–12:40 p.m. **Closing**

Break

12:40–1 p.m. EST

Virtual Exhibit & Poster Hall Hours

12:30–1:30 p.m. EST

Session 302: Late-Breaking Abstract Session

1–1:30 p.m. EST

Chair:

Roberta Zappasodi, PhD – *Weill Cornell Medicine*

1–1:15 p.m. **(795) A multicenter phase II trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)**
Micheal Wagner, MD – *University of Washington*

1:15 – 1:30 p.m. **(812) Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer**
Lei Zheng, MD, PhD – *Johns Hopkins University School of Medicine*

Session 303: Presidential Session

1:30–2:55 p.m. EST

Chair:

Mario Sznol, MD – *Yale School of Medicine*

1:30–1:35 p.m. **Introduction**
Mario Sznol, MD – *Yale School of Medicine*

1:35–1:50 p.m. **(528) Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b**
Defne Bayik, PhD - *Cleveland Clinic*

1:50–2:05 p.m. **(36) Molecular events regulating solid tumor cell responses to natural killer cells**
Michal Sheffer, PhD - *Dana-Farber Cancer Institute*

2:05–2:15 p.m. **Expert Discussant**
Jeffrey Miller, MD – *University of Minnesota*

2:15–2:30 p.m. **(629) Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody**
Emily Hsiue, MD - *Oncology*

2:30–2:45 p.m. **(465) Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection**
Nils Rudqvist, PhD - *The University of Texas MD Anderson Cancer Center*

2:45–2:55 p.m. **Expert Discussant**
Robert H. Vonderheide, MD, Dphil – *University of Pennsylvania Perelman School of Medicine*



Break

2:55–3:10 p.m. EST

Concurrent Session 304: Novel Immunotherapies in Myeloid Malignancies

3:10–4:40 p.m. EST

Co-Chairs:

Naval Daver, MD – *The University of Texas MD Anderson Cancer Center*

Marcela V. Maus, MD, PhD – *Massachusetts General Hospital*

3:10–3:30 p.m. **CD47 Macrophage Checkpoint-Based Immunotherapy (Lymphomas, MDS, AML)**

David Sallman, MD – *Moffitt Cancer Center*

3:30–3:50 p.m. **Bispecific Antibodies**

Marion Subklewe, MD – *University of Munich*

3:50–4:10 p.m. **CAR T for AML**

Elizabeth Budde, MD, PhD – *City of Hope*

4:10–4:40 p.m. **Emerging and personalized cellular therapy approaches for myeloid diseases**

Marco L. Davila, MD, PhD – *Moffitt Cancer Center*

Concurrent Session 305: Reverse Translation for Clinical Trials

3:10–4:40 p.m. EST

Co-Chairs:

Padmanee Sharma, MD, PhD – *The University of Texas MD Anderson Cancer Center*

Matthew D. Galsky, MD – *Tisch Cancer Institute at Mount Sinai*

3:10–3:30 p.m. **Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies through Reverse Translational Studies**

Sangeeta Goswami, MD, PhD – *The University of Texas MD Anderson Cancer Center*

3:30–3:50 p.m. **Clinical Trial Design Considerations to Facilitate Reverse Translation**

Thomas Marron, MD, PhD – *Icahn School of Medicine at Mount Sinai*

3:50–4:10 p.m. **Identifying Novel Therapeutics Targets to Overcome Immune Checkpoint Blockade Resistance Through Reverse Translation**

Sanjeev Mariathasan, PhD – *Genentech*

4:10–4:25 p.m. **(332) Novel TGF- β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab**

Keun-Wook Lee, MD, PhD – *Seoul National University College of Medicine*

4:25–4:40 p.m. **(352) Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab**

Ezra Cohen, MD – *University of California San Diego*

Concurrent Session 306: Engineering Immunity: Bimolecular and Genetic Approaches to Generating Novel Therapeutic Function

3:10–4:40 p.m. EST

Co-Chairs:

Yvonne Chen, PhD – *University of California, Los Angeles*

Kole T. Roybal, PhD – *University of California, San Francisco*

3:10–3:35 p.m. **Biomaterials – Basic Biology**



Jennifer H. Elisseeff, PhD – *Johns Hopkins School of Medicine*

3:35–4 p.m.

Biomaterials – Immunotherapy

Darrell J. Irvine, PhD – *MIT*

4–4:25 p.m.

Gene Editing

Amanda Lund, PhD – *NYU Grossman School of Medicine*

4:25–4:40 p.m.

(587) Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models

Kurt Jenkins, PhD – *Xilio Therapeutics*

Concurrent Session 307: B cells

3:10–4:40 p.m. EST

Co-Chairs:

Tullia C. Bruno, PhD – *UPMC Hillman Cancer Center*

Wolf H. Fridman, MD, PhD – *Cordeliers Research Centre*

3:10–3:30 p.m.

B cells and Tertiary Lymphoid Structures as biomarkers for prognosis and immunotherapy

Wolf H. Fridman, MD, PhD – *Cordeliers Research Centre*

3:30–3:50 p.m.

The Role of B cells and TLS in Immunotherapy Response

Jennifer Wargo, MD – *The University of Texas MD Anderson Cancer Center*

3:50–4:10 p.m.

Targeting tertiary lymphoid structure heterogeneity and B cell function in non-small cell lung cancer patients

Tullia C. Bruno, PhD – *UPMC Hillman Cancer Center*

4:10–4:17 p.m.

(536) Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures in head and neck cancer

Ayana Ruffin, MS – *University of Pittsburgh*

4:17–4:24 p.m.

(167) B-cell-based vaccination elicit potent immunity against glioblastoma

Catalina Lee-Chang, PhD – *Northwestern University*

4:24–4:30 p.m.

Expert Discussant

Brad Nelson, PhD – *Deeley Research Centre at BC Cancer Agency*

4:30–4:40 p.m.

Q&A

Session 308: E-Poster Viewing Session

4:40–5:10 p.m. EST

Virtual Exhibit & Poster Hall Hours

4:30–5:30 p.m.

Break

5:10–7 p.m. EST

Replay Session with Live Q&A: Late-Breaking Abstracts

7–8 p.m. EST

Chair:

Roberta Zappasodi, PhD – *Weill Cornell Medicine*



35th Anniversary Annual Meeting

Saturday, Nov. 14, 2020

Anniversary Award Ceremony

8:30–9 a.m. EST

Chair:

Mario Sznol, MD – *Yale School of Medicine*

8:30–8:32 a.m.

Introduction

Mario Sznol, MD – *Yale School of Medicine*

8:32–8:44 a.m.

Team Science Award

Session 400: 35th Anniversary Session: Mechanistic Understandings and Misunderstandings

9–10:30 a.m. EST

Chair:

James P. Allison, PhD – *The University of Texas MD Anderson Cancer Center*

John Wherry, PhD – *University of Pennsylvania*

9–9:30 a.m.

TBA

Ira Mellman, PhD – *Genentech*

9:30–10 a.m.

TBA

John Wherry, PhD – *University of Pennsylvania*

10–10:30 a.m.

TBA

Matthew Spitzer, PhD – *University of California San Francisco*

Break

10:30–10:45 a.m. EST

Session 401: Biomarkers and Big Data

10:45 a.m. –12:40 p.m. EST

Co-Chairs:

Michael Angelo, MD, PhD – *Stanford University*

Nir Hacohen, PhD – *Broad Institute*

10:45–10:55 a.m.

Introduction

Nir Hacohen, PhD – *Broad Institute*

10:55–11:20 a.m.

Spatial Analysis of Immune Responses in Tumors

Leeat Keren, PhD – *Stanford University*

11:20–11:45 a.m.

Blood-Based Predictors of Tumor Immunity

Jane Grogan, PhD – *ArsenalBio*

11:45 a.m.–12:10 p.m.


Capturing heterogeneity and the HLA-presented landscape in melanoma

Yardena Samuels, PhD – *Weizmann Institute of Science*

12:10–12:25 p.m.

(62) Identify immune cell types and biomarkers associated with immune-related adverse events using single cell RNA sequencing

Jiamin Chen, PhD – *Stanford University Medical School*



12:25–12:40 p.m. **(21) Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients**
Michal Harel, PhD – *Oncohost LTD*

Break

12:40 –1 p.m. EST

Virtual Exhibit & Poster Hall Hours

12:30 –1:30 p.m. EST

Session 402: E-Poster Viewing Session

1–1:30 p.m. EST

Session 403: Poster Symposium

1:30 –2:45 p.m. EST

Co-Chairs:

Niroshana Anandasabapathy, MD, PhD – *Weill Cornell Medicine*

Sangeeta Goswami, MD, PhD – *The University of Texas MD Anderson Cancer Center*

1:30 –1:40 p.m. **(545) Tumor-specific cytotoxic CD4 T cells mediate protective immunity against human cancer**
Camilla Jandus, MD, PhD – *University of Geneva*

1:40–1:50 p.m. **(206) An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer**
Elizabeth R. Stirling, MS – *Wake Forest University*

1:50–2 p.m. **(549) Characterizing Double Positive T cells in the Tumor Microenvironment: a tale of promiscuous cell fates**
Sara Schad, BS – *Memorial Sloan Kettering Cancer Center*

2–2:10 p.m. **(152) Adoptive T cell therapy targeting somatic p53 mutations**
Peter Kim, PhD – *National Institute of Health*

2:10–2:20 p.m. **(744) Single cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy**
Hussein Abbas, MD, PhD – *The University of Texas MD Anderson Cancer Center*

2:20–2:30 p.m. **(248) Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing**
Kartik Sehgal, MD – *Dana-Farber Cancer Institute*

2:30–2:45 p.m. **Q&A**

Break

2:45–3 p.m. EST

Session 404: Next Generation Immunotherapy Combinations: Navigating FDA, Clinical Trial Design, Diagnostics and Novel Biomarkers

3–4:30 p.m. EST

Co-Chairs


Emily Hopewell, PhD, MT – *Indiana University*

Ke Liu, MD, PhD – *Food and Drug Administration (FDA)*

Jason Luke, MD, FACP – *UPMC*

Marc Theoret, MD – *Food and Drug Administration (FDA), CDER, OHOP*

3–3:05 p.m. **Welcome**
Jason Luke, MD – *UPMC Hillman Cancer Center*



- 3:05–3:20 p.m. **Navigating the Road to Developing and Pursuing Novel Cellular and Non-Cellular Combination Immunotherapy Clinical Trials: FDA Overview**
Adnan A. Jaigirdar, MD, FACS – *Food and Drug Administration*
- 3:20–3:35 p.m. **FDA Perspective on Areas of Research Needed in Advancing Neo-Adjuvant Immunotherapy Toward Clinical Practice**
Nicole Drezner, MD – *Food and Drug Administration*
- 3:35–3:50 p.m. **Difficulties and opportunities in developing cellular therapy and cancer therapeutics clinical trials: science and logistics for investigators**
Cassian Yee, MD – *The University of Texas MD Anderson Cancer Center*
- 3:50–4:05 p.m. **Improving patient selection in cellular therapy studies and neoadjuvant trials**
Rodabe N. Amaria, MD – *The University of Texas MD Anderson Cancer Center*
- 4:05–4:30 p.m. **Panel Discussion**

Closing Remarks

4:30 p.m. EST

On-Demand Session

Update Session: National Cancer Institute (NCI)

Norman E. Sharpless, MD – *National Cancer Institute*

Update Session: Food and Drug Administration (FDA)

Raj Puri, MD, PhD – *U.S. Food and Drug Administration*

Update Session: FDA Oncology Center of Excellence (FDA OCE)

Marc Theoret, MD – *U.S. Food and Drug Administration, OHOP*

Update Session: Cancer Immunotherapy Trials Network (CITN)

Martin A. Cheever, MD Fred - *Hutchinson Cancer Research Center*

Update Session: SITC Policy Committee

George J. Weiner, MD - *University of Iowa, Holden Comprehensive Cancer Center*

Update Session: Women in Cancer Immunotherapy Network (WIN)

Lisa H. Butterfield, PhD – *Parker Institute for Cancer Immunotherapy*

Update Session: International Neoadjuvant Melanoma Consortium (INMC)

Elizabeth M. Burton, MBA – *The University of Texas MD Anderson Cancer Center*